"Hypogonadism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Descriptor ID |
D007006
|
| MeSH Number(s) |
C19.391.482
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hypogonadism".
Below are MeSH descriptors whose meaning is more specific than "Hypogonadism".
This graph shows the total number of publications written about "Hypogonadism" by people in this website by year, and whether "Hypogonadism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2011 | 4 | 1 | 5 |
| 2012 | 7 | 0 | 7 |
| 2013 | 7 | 1 | 8 |
| 2014 | 14 | 2 | 16 |
| 2015 | 9 | 2 | 11 |
| 2016 | 8 | 2 | 10 |
| 2017 | 9 | 1 | 10 |
| 2018 | 6 | 3 | 9 |
| 2019 | 4 | 2 | 6 |
| 2020 | 9 | 2 | 11 |
| 2021 | 9 | 3 | 12 |
| 2022 | 5 | 0 | 5 |
| 2023 | 4 | 0 | 4 |
| 2024 | 2 | 0 | 2 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypogonadism" by people in Profiles.
-
Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e814-e826.
-
PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/?-CATENIN Pathway in Testosterone-Treated Hypogonadal Men. Biomolecules. 2025 Jan 08; 15(1).
-
A PRDM16-driven signal regulates body composition in testosterone-treated hypogonadal men. Front Endocrinol (Lausanne). 2024; 15:1426175.
-
Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
-
Impact of ovarian insufficiency on bone health in childhood cancer survivors: Two cases. Bone. 2024 01; 178:116930.
-
Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jul 13; 389(2):107-117.
-
Oral testosterone therapy: past, present, and future. Sex Med Rev. 2023 04 03; 11(2):124-138.
-
Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy. Front Endocrinol (Lausanne). 2022; 13:915309.
-
Hypogonadism Associated With Higher Rate of Penile Prosthesis Infection: An Analysis of United States Claims Data. Urology. 2022 09; 167:132-137.